H.C. Wainwright Reiterates Buy Rating on Kairos Pharma (KAPA)

April 21, 2025 6:53 AM EDT Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $12.00 price target on Kairos Pharma (NYSE: KAPA).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login